Detalles de la búsqueda
1.
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials.
Hematol Oncol
; 40(4): 704-715, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35608183
2.
Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study).
Ann Hematol
; 98(2): 361-367, 2019 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-30353388
3.
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials.
Haematologica
; 106(1): 291-294, 2021 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32107338
4.
Combined use of free light chain and heavy/light chain ratios allow diagnosis and monitoring of patients with monoclonal gammopathies: Experience of a single institute, with three exemplar case reports.
Oncol Lett
; 12(4): 2363-2370, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27698801
Resultados
1 -
4
de 4
1
Próxima >
>>